• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用大量公开的转录组序列数据系统地建立一个剪接位点创建变体的登记册。

Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data.

作者信息

Iida Naoko, Okada Ai, Kobayashi Yoshihisa, Chiba Kenichi, Yatabe Yasushi, Shiraishi Yuichi

机构信息

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.

出版信息

Nat Commun. 2025 Jan 9;16(1):426. doi: 10.1038/s41467-024-55185-y.

DOI:10.1038/s41467-024-55185-y
PMID:39788962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11718197/
Abstract

Genomic variants causing abnormal splicing play important roles in genetic disorders and cancer development. Among them, variants that cause the formation of novel splice-sites (splice-site creating variants, SSCVs) are particularly difficult to identify and often overlooked in genomic studies. Additionally, these SSCVs are frequently considered promising candidates for treatment with splice-switching antisense oligonucleotides (ASOs). To leverage massive transcriptome sequence data such as those available from the Sequence Read Archive, we develop a novel framework to screen for SSCVs solely using transcriptome data. We apply it to 322,072 publicly available transcriptomes and identify 30,130 SSCVs. Among them, 5121 SSCVs affect disease-causing variants. By utilizing this extensive collection of SSCVs, we reveal the characteristics of Alu exonization via SSCVs, especially the hotspots of SSCVs within Alu sequences and their evolutionary relationships. We discover novel gain-of-function SSCVs in the deep intronic region of the NOTCH1 gene and demonstrate that their activation can be suppressed using splice-switching ASOs. Collectively, we provide a systematic approach for automatically acquiring a registry of SSCVs, which facilitates the elucidation of novel biological mechanisms underlying splicing and serves as a valuable resource for drug discovery. The catalogs of SSCVs identified in this study are accessible on the SSCV DB ( https://sscvdb.io ).

摘要

导致异常剪接的基因组变异在遗传疾病和癌症发展中起着重要作用。其中,导致新剪接位点形成的变异(剪接位点创建变异,SSCVs)尤其难以识别,并且在基因组研究中常常被忽视。此外,这些SSCVs经常被认为是使用剪接转换反义寡核苷酸(ASOs)进行治疗的有前景的候选对象。为了利用大规模转录组序列数据,例如可从序列读取存档中获得的数据,我们开发了一种仅使用转录组数据来筛选SSCVs的新框架。我们将其应用于322,072个公开可用的转录组,并识别出30,130个SSCVs。其中,5121个SSCVs影响致病变异。通过利用这一广泛收集的SSCVs,我们揭示了通过SSCVs发生的Alu外显子化的特征,特别是Alu序列内SSCVs的热点及其进化关系。我们在NOTCH1基因的内含子深处区域发现了新的功能获得性SSCVs,并证明可以使用剪接转换ASOs抑制它们的激活。总体而言,我们提供了一种系统方法来自动获取SSCVs的登记册,这有助于阐明剪接背后的新生物学机制,并作为药物发现的宝贵资源。本研究中识别出的SSCVs目录可在SSCV DB(https://sscvdb.io)上获取。

相似文献

1
Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data.利用大量公开的转录组序列数据系统地建立一个剪接位点创建变体的登记册。
Nat Commun. 2025 Jan 9;16(1):426. doi: 10.1038/s41467-024-55185-y.
2
Disease-causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE-2 and antisense Alu lacking the poly(T)-tail.导致疾病的突变改善分支位点和多嘧啶序列:缺乏聚(T)尾的LINE-2和反义Alu的假外显子激活。
Hum Mutat. 2009 May;30(5):823-31. doi: 10.1002/humu.20969.
3
Minimal conditions for exonization of intronic sequences: 5' splice site formation in alu exons.内含子序列外显子化的最低条件:alu外显子中5'剪接位点的形成。
Mol Cell. 2004 Apr 23;14(2):221-31. doi: 10.1016/s1097-2765(04)00181-9.
4
Alu insertion variants alter mRNA splicing.Alu 插入变异改变 mRNA 剪接。
Nucleic Acids Res. 2019 Jan 10;47(1):421-431. doi: 10.1093/nar/gky1086.
5
Intronic antisense Alu elements have a negative splicing effect on the inclusion of adjacent downstream exons.内含子反义 Alu 元件对相邻下游外显子的内含具有负性剪接效应。
Gene. 2018 Jul 20;664:84-89. doi: 10.1016/j.gene.2018.04.064. Epub 2018 Apr 23.
6
Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.杂交介导的剪接转换反义寡核苷酸的脱靶效应。
Nucleic Acids Res. 2020 Jan 24;48(2):802-816. doi: 10.1093/nar/gkz1132.
7
Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene.反义寡核苷酸拯救 6- 吡咯啉 -5- 羧酸合成酶基因中激活假外显子的深内含子变异。
Nucleic Acid Ther. 2022 Oct;32(5):378-390. doi: 10.1089/nat.2021.0066. Epub 2022 Jul 12.
8
Exonization of transposed elements: A challenge and opportunity for evolution.转座子外显子化:进化的挑战与机遇。
Biochimie. 2011 Nov;93(11):1928-34. doi: 10.1016/j.biochi.2011.07.014. Epub 2011 Jul 26.
9
Multifactorial interplay controls the splicing profile of Alu-derived exons.多因素相互作用控制着源自Alu元件的外显子的剪接模式。
Mol Cell Biol. 2008 May;28(10):3513-25. doi: 10.1128/MCB.02279-07. Epub 2008 Mar 10.
10
MutSpliceDB: A database of splice sites variants with RNA-seq based evidence on effects on splicing.MutSpliceDB:一个基于 RNA-seq 证据的剪接位点变异数据库,用于研究其对剪接的影响。
Hum Mutat. 2021 Apr;42(4):342-345. doi: 10.1002/humu.24185. Epub 2021 Mar 1.

引用本文的文献

1
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.基于新抗原的免疫疗法:通过发现与创新推动癌症和胶质母细胞瘤治疗的精准医学发展。
Explor Target Antitumor Ther. 2025 Apr 27;6:1002313. doi: 10.37349/etat.2025.1002313. eCollection 2025.

本文引用的文献

1
Pharmacological reactivation of p53 in the era of precision anticancer medicine.精准抗癌医学时代的 p53 药理学再激活。
Nat Rev Clin Oncol. 2024 Feb;21(2):106-120. doi: 10.1038/s41571-023-00842-2. Epub 2023 Dec 15.
2
Estimating the proportion of nonsense variants undergoing the newly described phenomenon of manufactured splice rescue.估计有多少无义变异体经历了新描述的制造剪接拯救现象。
Eur J Hum Genet. 2024 Feb;32(2):238-242. doi: 10.1038/s41431-023-01495-6. Epub 2023 Nov 27.
3
A framework for individualized splice-switching oligonucleotide therapy.
个体化剪接寡核苷酸治疗的框架。
Nature. 2023 Jul;619(7971):828-836. doi: 10.1038/s41586-023-06277-0. Epub 2023 Jul 12.
4
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).ACMG SF v3.2 临床外显子组和基因组测序中报告次要发现的列表:美国医学遗传学与基因组学学会 (ACMG) 的政策声明。
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
5
Aberrant splicing prediction across human tissues.跨人类组织的异常剪接预测
Nat Genet. 2023 May;55(5):861-870. doi: 10.1038/s41588-023-01373-3. Epub 2023 May 4.
6
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.癌症中的突变型 p53:从分子机制到治疗调节。
Cell Death Dis. 2022 Nov 18;13(11):974. doi: 10.1038/s41419-022-05408-1.
7
Evaluating human mutation databases for "treatability" using patient-customized therapy.利用患者定制疗法评估人类突变数据库的“可治疗性”。
Med. 2022 Nov 11;3(11):740-759. doi: 10.1016/j.medj.2022.08.006.
8
Systematic identification of intron retention associated variants from massive publicly available transcriptome sequencing data.从海量公开转录组测序数据中系统地鉴定内含子保留相关变异。
Nat Commun. 2022 Sep 29;13(1):5357. doi: 10.1038/s41467-022-32887-9.
9
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.融合基因的基因组和生物学研究作为对 EGFR 抑制剂的耐药机制。
Nat Commun. 2022 Sep 24;13(1):5614. doi: 10.1038/s41467-022-33210-2.
10
High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios.对扩展的 1000 基因组项目队列进行高覆盖率全基因组测序,包括 602 个三核苷酸重复序列。
Cell. 2022 Sep 1;185(18):3426-3440.e19. doi: 10.1016/j.cell.2022.08.004.